U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H24Cl2N2O
Molecular Weight 355.302
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of U-54494A

SMILES

CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)C3=CC=C(Cl)C(Cl)=C3

InChI

InChIKey=JUBNVWGVNWIXMB-IAGOWNOFSA-N
InChI=1S/C18H24Cl2N2O/c1-21(18(23)13-8-9-14(19)15(20)12-13)16-6-2-3-7-17(16)22-10-4-5-11-22/h8-9,12,16-17H,2-7,10-11H2,1H3/t16-,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H24Cl2N2O
Molecular Weight 355.302
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

U-54494A is a unique and selective anticonvulsant agent acting by a Ca(2+)-related mechanism possibly through a subclass of kappa receptors. Voltage- and use-dependent block of the Na and K channels by U-54494A may be an important pharmacological basis for its anticonvulsant action. U-54494A, a racemic mixture of two enantiomers, is being developed and pre-clinically tested as an anticonvulsant drug candidate.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Voltage-dependent sodium channels (mice)
72.0 µM [IC50]
Target ID: Voltage-gated potassium channels (mice)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Two metabolites of anticonvulsant U-54494A: their anticonvulsant activity and interaction with sodium channel.
1993 Mar 19
Anticonvulsant and related effects of U-54494A in various seizure tests.
1993 Oct
First-pass effect of cis-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)- cyclohexyl)-benzamide (U-54494) in rats--a model with multiple cannulas for investigation of gastrointestinal and hepatic metabolism.
1994 Nov
The effects of anticonvulsant agents on 4-aminopyridine induced epileptiform activity in rat hippocampus in vitro.
1995 Feb
Pharmacokinetics of the individual enantiomers of cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzamide monohydrochloride (U-54494A) in the dog.
1996
Patents

Sample Use Guides

Mice Intraperitoneal: ED50 = 28 mg/kg (15 min) and 38 mg/kg (30 min) Mice Oral: ED50 = 61 mg/kg (30 min) and 65 mg/kg (60 min) Mice Subcutaneous: ED50 = 24 mg/kg (15 min)
Route of Administration: Other
In Vitro Use Guide
At a concentration of 100 microM, U-54494A significantly reduced the availability of cytosolic free calcium (Ca2+) in depolarized MF-enriched synaptosomes by 30% and inhibited the K(+)-evoked release of endogenous glutamate by 85%.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:42:27 GMT 2023
Edited
by admin
on Fri Dec 15 19:42:27 GMT 2023
Record UNII
I3NE36R0XJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
U-54494A
Common Name English
BENZAMIDE, 3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)CYCLOHEXYL)-, TRANS-
Systematic Name English
Code System Code Type Description
FDA UNII
I3NE36R0XJ
Created by admin on Fri Dec 15 19:42:27 GMT 2023 , Edited by admin on Fri Dec 15 19:42:27 GMT 2023
PRIMARY
PUBCHEM
122015
Created by admin on Fri Dec 15 19:42:27 GMT 2023 , Edited by admin on Fri Dec 15 19:42:27 GMT 2023
PRIMARY
EPA CompTox
DTXSID60918854
Created by admin on Fri Dec 15 19:42:27 GMT 2023 , Edited by admin on Fri Dec 15 19:42:27 GMT 2023
PRIMARY
CAS
92953-41-8
Created by admin on Fri Dec 15 19:42:27 GMT 2023 , Edited by admin on Fri Dec 15 19:42:27 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT